An interventional study of HistoSonics Investigational System in Renal Cancer, Tumor, Solid and Kidney Cancer, sponsored by HistoSonics, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Kidney Neoplasms with a site in United Kingdom — 12 open to participants now, 15 under way, 2 of them phase 3. Kidney Neoplasms · United Kingdom.
Among the 66 studies in Kidney Neoplasms with a site in United Kingdom, this one is the 47th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 with no phase, and was the 55th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.
Browse Kidney Neoplasms studies →12 of the 66 studies in Kidney Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Cambridge · Sites in United Kingdom
Ages 55–70 · Healthy volunteers
Arcus Biosciences, Inc. · Sites in United Kingdom, United States, Argentina and 14 more countries
Ages 18+
British Urology Researchers in Surgical Training · Sites in United Kingdom
Ages 18+
Cancer Research UK · Sites in United Kingdom
Ages 18+
University of Cambridge · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 16
First in 1995; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 126 across the 52 interventional studies, 182 across the 11 observational. Of the 39 that completed or were terminated, 16 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 66 have an industry lead sponsor. The 10 most frequent:
HistoSonics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
HistoSonics, Inc. has 2 studies filed under Kidney Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Kidney Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
| NCT07171190University of CambridgeTargeted Abdominal CT in Conjunction With Lung Cancer Screening | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 66 studies in Kidney Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.
This trial is a prospective, multi-center, single-arm pilot trial designed to evaluate the effectiveness and safety profile of the HistoSonics Investigational System in treating primary solid renal tumors. Following histotripsy treatment of the solid renal tumor, subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Additionally, subjects will be followed 180 days (6 months) post-index procedure, with evaluations at the 14-day, 30-day, 90-day, and 180-day time points to establish the efficacy and safety profile of the HistoSonics Investigational System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject meets all the following functional criteria at ≤14 days prior to the planned index procedure date:
(INR) score of \<1.5:
Exclusion Criteria:
Subject has a genetic predisposition to kidney cancer such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: HistoSonics Investigational System
The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
Also known as: Histotripsy
Primary Effectiveness: Technical Success
Technical success, defined as complete coverage of the tumor as determined ≤36 hours post-index procedure by magnetic resonance imaging (MRI) or computerized tomography (CT). \[Core Lab Adjudicated\]
Time frame: Up to 36 hours after the index procedure
Primary Safety: Freedom From Index Procedure Related Major Complications
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the last histotripsy procedure. \[Clinical Events Committee Adjudicated\]
Time frame: 30 days Post-Index Procedure
Technique Efficacy (Primary)
The secondary endpoint of Technique Efficacy (Primary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure without repeat Histotripsy \[Core Lab Adjudicated\]
Time frame: 90 days Post-Index Procedure
Technique Efficacy (Secondary)
The secondary endpoint of Technique Efficacy (Secondary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure either without or with repeat Histotripsy \[Core Lab Adjudicated\]
Time frame: 90 days Post-Index Procedure
The trial enrolled participants between March 2023 and November 2024 at one (1) UK site. All eligible subjects who provided informed consent were considered enrolled. Only subjects enrolled and treated with the HistoSonics Investigational System were assessed for the primary and secondary endpoints.
| Milestone | HistoSonics Investigational System |
|---|---|
| Started | 20 |
| Screen failures | 9 |
| Completed | 11 |
| Not completed | 9 |
| Milestone | HistoSonics Investigational System |
|---|---|
| Started | 11 |
| Completed | 11 |
| Not completed | 0 |
Technical success, defined as complete coverage of the tumor as determined ≤36 hours post-index procedure by magnetic resonance imaging (MRI) or computerized tomography (CT). \[Core Lab Adjudicated\]
| percentage of tumors | HistoSonics Investigational System |
|---|---|
| Primary Effectiveness: Technical Success | 100.0 (71.5 to 100.0) |
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the last histotripsy procedure. \[Clinical Events Committee Adjudicated\]
| percentage of participants | HistoSonics Investigational System |
|---|---|
| Primary Safety: Freedom From Index Procedure Related Major Complications | 90.9 (58.7 to 99.8) |
The secondary endpoint of Technique Efficacy (Primary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure without repeat Histotripsy \[Core Lab Adjudicated\]
| percentage of tumors | HistoSonics Investigational System |
|---|---|
| Technique Efficacy (Primary) | 70.0 (34.8 to 93.3) |
The secondary endpoint of Technique Efficacy (Secondary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure either without or with repeat Histotripsy \[Core Lab Adjudicated\]
| percentage of tumors | HistoSonics Investigational System |
|---|---|
| Technique Efficacy (Secondary) | 70.0 (34.8 to 93.3) |
Collected over Histotripsy treatment through 180-day visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HistoSonics Investigational System | 0/11 (0%) | 5/11 (45.5%) | 11/11 (100%) |
| Event | HistoSonics Investigational System |
|---|---|
| Renal neoplasmRenal and urinary disorders | 2/11 |
| VomitingGastrointestinal disorders | 1/11 |
| Urinary retention postoperativeInjury, poisoning and procedural complications | 1/11 |
| EmphysemaRespiratory, thoracic and mediastinal disorders | 1/11 |
| Obstructive airways disorderRespiratory, thoracic and mediastinal disorders | 1/11 |
| Abdominal painGastrointestinal disorders | 1/11 |
| Event | HistoSonics Investigational System |
|---|---|
| HaematuriaRenal and urinary disorders | 10/11 |
| ConstipationGastrointestinal disorders | 4/11 |
| Back painMusculoskeletal and connective tissue disorders | 4/11 |
| VomitingGastrointestinal disorders | 3/11 |
| Influenza like illnessGeneral disorders | 3/11 |
| Abdominal pain lowerGastrointestinal disorders | 2/11 |
| PainGeneral disorders | 2/11 |
| Decreased appetiteGeneral disorders | 2/11 |
| White blood cell count increasedInvestigations | 2/11 |
| HeadacheNervous system disorders | 2/11 |
Participants treated with histotripsy
| Age, Continuous(years) | HistoSonics Investigational System |
|---|---|
| Median | 71.0 (59.0 to 79.0) |
| Sex: Female, Male(Participants) | HistoSonics Investigational System |
|---|---|
| Female | 4 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | HistoSonics Investigational System |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | HistoSonics Investigational System |
|---|---|
| White | 10 |
| Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Dec 2024, 21 months.
Results were first posted in Dec 2025, 11 months after primary completion.
Of 97 interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 90. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HistoSonics, Inc.